Neoadjuvant Therapy Schemes combined with adjuvant Therapy for Patients with muscle invasive Bladder Cancer before or after radical Cystectomy A randomized, open, multicenter, global Phase-III Study to Determine the Efficacy and Safety of Durvalumab in combination with Gemcitabine plus Cisplatin (G plus C) for neoadjuvant Treatment, followed by Durvalumab alone for adjuvant Treatment in Patients with muscle invasive Bladder Cancer ( NIAGARA) - AUO AB 74/20